Cancer and venous thrombosis: Current comprehensions and future perspectives

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 5, 2013, Pages 507-514

  Lauw, Mandyn ^a   Van Doormaal, Frederiekf ^a   Middeldorp, Saskia ^a   Buller, Harryr ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

cancer; incidental thrombosis; risk assessment; thromboprophylaxis; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; CERTOPARIN; DALTEPARIN; ENOXAPARIN; GEMCITABINE; HEMOGLOBIN; LENALIDOMIDE; NADROPARIN; PLACEBO; SEMULOPARIN; WARFARIN;

ADVANCED CANCER; BLADDER CANCER; BODY MASS; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; CHEMOPROPHYLAXIS; DISEASE SEVERITY; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LUNG CANCER; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; NEOPLASM; OCCULT CANCER; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SOLID TUMOR; STOMACH CANCER; TESTIS CANCER; THROMBOCYTE COUNT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84879108096     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1343891     Document Type: Review

References (80)

1. Bouillaud S. De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med: 1823; 1 188 204
2. Trousseau A. Phlegmasia alba dolens. In: Trousseau ed. Clinique medicinale de l'Hotel-Dieu de Paris. Paris Bailliere J.-B. et fils: 1865; 645 712
3. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol: 2005; 6 6 401 410
4. Rickles F. R., Edwards R. L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood: 1983; 62 1 14 31
5. Chew H. K., Wun T., Harvey D., Zhou H., White R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med: 2006; 166 4 458 464
6. Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost: 2007; 5 3 632 634
7. Heit J. A., Mohr D. N., Silverstein M. D., Petterson T. M., O'Fallon W. M., Melton L. J. III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med: 2000; 160 6 761 768
8. Blom J. W., Vanderschoot J. P., Oostindiër M. J., Osanto S., van der Meer F. J., Rosendaal F. R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost: 2006; 4 3 529 535
9. Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA: 2005; 293 6 715 722
10. Horsted F., West J., Grainge M. J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med: 2012; 9 7 e1001275
11. Mandala M., Clerici M., Corradino I., et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol: 2012; 23 6 1416 1421
12. Vemulapalli S., Chintala L., Tsimberidou A. M., et al. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol: 2009; 84 7 408 413
13. White R. H., Chew H. K., Zhou H., et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med: 2005; 165 15 1782 1787
14. Falanga A., Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol: 2009; 27 29 4848 4857
15. Heit J. A. Cancer and venous thromboembolism: scope of the problem. Cancer Contr: 2005; 12 01 5 10
16. Lauw M. N., Van der Holt B., Middeldorp S., Meijers J. C., Cornelissen J., Biemond B. J. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. Thromb Haemost: 2013; 109 4 109
17. Mitchell L., Lambers M., Flege S., et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood: 2010; 115 24 4999 5004
18. Otten H. M., Mathijssen J., ten Cate H., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med: 2004; 164 2 190 194
19. Haddad T. C., Greeno E. W. Chemotherapy-induced thrombosis. Thromb Res: 2006; 118 5 555 568
20. Palumbo A., Rajkumar S. V., Dimopoulos M. A., et al. International Myeloma Working Group Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia: 2008; 22 2 414 423
21. Heit J. A., Mohr D. N., Silverstein M. D., Petterson T. M., O'Fallon W. M., Melton L. J. III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med: 2000; 160 6 761 768
22. Prandoni P., Lensing A. W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood: 2002; 100 10 3484 3488
23. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol: 2005; 6 6 401 410
24. Sorensen H. T., Mellemkjaer L., Olsen J. H., Baron J. A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med: 2000; 343 25 1846 1850
25. Trujillo-Santos J., Nieto J. A., Ruíz-Gamietea A., et al. RIETE Investigators Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res: 2010; 125 02 S58 S61
26. Mandalà M., Falanga A., Roila F. ESMO Guidelines Working Group Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol: 2011; 22 06 vi85 vi92
27. Kahn S. R., Lim W., Dunn A. S., et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 e195S e226S
28. Lyman G. H., Khorana A. A., Falanga A., et al. American Society of Clinical Oncology American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol: 2007; 25 34 5490 5505
29. Khorana A. A., Dalal M., Lin J., Connolly G. C. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer: 2013; 119 3 648 655
30. Larocca A., Cavallo F., Bringhen S., et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood: 2012; 119 4 933 939, quiz 1093
31. Palumbo A., Cavo M., Bringhen S., et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol: 2011; 29 8 986 993
32. Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet: 1994; 343 8902 886 889
33. Maraveyas A., Waters J., Roy R., et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer: 2012; 48 9 1283 1292
34. Perry J. R., Julian J. A., Laperriere N. J., et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost: 2010; 8 9 1959 1965
35. Agnelli G., Gussoni G., Bianchini C., et al. PROTECHT Investigators Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol: 2009; 10 10 943 949
36. Agnelli G., George D. J., Kakkar A. K., et al. SAVE-ONCO Investigators Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med: 2012; 366 7 601 609
37. Haas S. K., Freund M., Heigener D., et al. TOPIC Investigators Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost: 2012; 18 2 159 165
38. Di Nisio M., Porreca E., Ferrante N., Otten H. M., Cuccurullo F., Rutjes A. W. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev: 2012; 2 CD008500
39. Sideras K., Schaefer P. L., Okuno S. H., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc: 2006; 81 6 758 767
40. Altinbas M., Coskun H. S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost: 2004; 2 8 1266 1271
41. Kakkar A. K., Levine M. N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol: 2004; 22 10 1944 1948
42. Mitchell L., Andrew M., Hanna K., et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost: 2003; 90 2 235 244
43. Riess H., Pelzer U., Hilbig A., et al. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer: 2008; 8 361
44. Levine M. N., Gu C., Liebman H. A., et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost: 2012; 10 5 807 814
45. Khorana A. A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood: 2008; 111 10 4902 4907
46. Ay C., Dunkler D., Marosi C., et al. Prediction of venous thromboembolism in cancer patients. Blood: 2010; 116 24 5377 5382
47. Moore R. A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol: 2011; 29 25 3466 3473
48. Thaler J., Ay C., Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost: 2012; 108 6 1042 1048
49. Verso M., Agnelli G., Barni S., Gasparini G., LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med: 2012; 7 3 291 292
50. Mandalà M., Barni S., Prins M., et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol: 2010; 21 4 871 876
51. Ay C., Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res: 2012; 129 01 S6 S9
52. Zwicker J. I., Liebman H. A., Bauer K. A., et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol: 2012; 160 4 530 537
53. Browne A. M., Cronin C. G., English C., NiMhuircheartaigh J., Murphy J. M., Bruzzi J. F. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol: 2010; 5 6 798 803
54. Sebastian A. J., Paddon A. J. Clinically unsuspected pulmonary embolism-an important secondary finding in oncology CT. Clin Radiol: 2006; 61 1 81 85
55. Storto M. L., Di Credico A., Guido F., Larici A. R., Bonomo L. Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol: 2005; 184 1 264 267
56. Douma R. A., Kok M. G., Verberne L. M., Kamphuisen P. W., Büller H. R. Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res: 2010; 125 6 e306 e309
57. Dentali F., Ageno W., Becattini C., et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res: 2010; 125 6 518 522
58. Carrier M., Righini M., Wells P. S., et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost: 2010; 8 8 1716 1722
59. Ageno W., Squizzato A., Togna A., et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost: 2012; 10 1 158 160
60. Di Nisio M., Ferrante N., De Tursi M., et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost: 2010; 104 5 1049 1054
61. Menapace L. A., Peterson D. R., Berry A., Sousou T., Khorana A. A. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost: 2011; 106 2 371 378
62. Font C., Farrús B., Vidal L., et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol: 2011; 22 9 2101 2106
63. den Exter P. L., Hooijer J., Dekkers O. M., Huisman M. V. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol: 2011; 29 17 2405 2409
64. O'Connell C., Razavi P., Ghalichi M., et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost: 2011; 9 2 305 311
65. Dentali F., Ageno W., Pierfranceschi M. G., et al. Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. J Thromb Haemost: 2011; 9 5 1081 1083
66. Trujillo-Santos J., Prandoni P., Rivron-Guillot K., et al. RIETE Investigators Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost: 2008; 6 2 251 255
67. Otten H. M., Prins M. H. Venous thromboembolism and occult malignancy. Thromb Res: 2001; 102 6 V187 V194
68. Douketis J. D., Gu C., Piccioli A., Ghirarduzzi A., Pengo V., Prandoni P. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost: 2009; 7 4 546 551
69. Monreal M., Fernandez-Llamazares J., Perandreu J., Urrutia A., Sahuquillo J. C., Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost: 1997; 78 5 1316 1318
70. Monreal M., Lafoz E., Casals A., et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer: 1991; 67 2 541 545
71. Lee A. Y. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology (Am Soc Hematol Educ Program): 2006; 438 443
72. Piccioli A., Lensing A. W., Prins M. H., et al. SOMIT Investigators Group Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost: 2004; 2 6 884 889
73. Cornuz J., Pearson S. D., Creager M. A., Cook E. F., Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med: 1996; 125 10 785 793
74. Hettiarachchi R. J., Lok J., Prins M. H., Büller H. R., Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer: 1998; 83 1 180 185
75. Nordström M., Lindblad B., Anderson H., Bergqvist D., Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ: 1994; 308 6933 891 894
76. Van Doormaal F. F., Terpstra W., Van Der Griend R., et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost: 2011; 9 1 79 84
77. Bastounis E. A., Karayiannakis A. J., Makri G. G., Alexiou D., Papalambros E. L. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med: 1996; 239 2 153 156
78. Monreal M., Lensing A. W., Prins M. H., et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost: 2004; 2 6 876 881
79. Sannella N. A., O'Connor D. J. Jr. "Idiopathico" deep venous thrombosis: the value of routine abdominal and pelvic computed tomographic scanning. Ann Vasc Surg: 1991; 5 3 218 222
80. Carrier M., Le Gal G., Wells P. S., Fergusson D., Ramsay T., Rodger M. A. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med: 2008; 149 5 323 333